The United Bio-technology (hengqin) Co., Ltd.
Clinical trials sponsored by The United Bio-technology (hengqin) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New diabetes shot UBT38006 enters first human safety trial Results expected Oct 2026 (estimated)
- Could a new Weight-Loss drug play well with others? a trial investigates Results expected Dec 2026 (estimated)
- New weekly shot aims to reverse fatty liver damage Results expected Jun 2027 (estimated)
-
New weekly shot could help control blood sugar in type 2 diabetes
Disease control CompletedThis study tested a new once-weekly injection called UBT251 in 211 adults with type 2 diabetes. Participants received either UBT251, a placebo, or the existing drug semaglutide for 24 weeks. The main goal was to see how well UBT251 lowers blood sugar (HbA1c) and to find the right…
Phase 2 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
New weekly injection shows promise for obesity – phase 2 trial complete
Disease control CompletedThis study tested a new weekly injection called UBT251 in 205 overweight or obese adults to see if it helps with weight loss. Participants received different doses of the drug or a placebo for 24 weeks. The main goal was to measure the percentage change in body weight, with addit…
Phase 2 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC